

Vietnam Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Vietnam				
2. Grant number: 1719-VNM-04a-X / 08-VNM-08c-Y				
3. Date of Decision Letter: 13 December 2017				
4. Date of the Partnership Framework Agreement: 9 October 2013				
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine				
6. Vaccine type: Pentavalent				
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID				
8. Programme duration¹: 2009 -2019				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)				
	2009-2017	2018	2019	Total²
Programme Budget (US\$)	87,462,371 ³	966,500	777,500	89,206,371
10. Vaccine introduction grant (in US\$): . US\$492,500 already disbursed on 23.9.2008				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴				
Type of supplies to be purchased with Gavi funds in each year	2009-2017	2018		
Number of Pentavalent vaccines doses		833,200		
Annual Amounts (US\$)	87,462,371 ⁵	966,500		
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
13. Self-procurement: Not applicable				

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>14. Co-financing obligations: Reference code: 1719-VNM-04a-X-C</p> <p>According to the co-financing policy, the Country falls within the group Accelerated transition as of 1 January 2015.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>																							
<table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2018</th> <th>2019</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>4,646,500</td> <td>5,085,700</td> </tr> <tr> <td>Number of AD syringes</td> <td>4,861,500</td> <td></td> </tr> <tr> <td>Number of re-constitution syringes</td> <td></td> <td></td> </tr> <tr> <td>Number of safety boxes</td> <td>53,500</td> <td></td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>5,018,145</td> <td></td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>5,607,500</td> <td>US\$5,985,500</td> </tr> </tbody> </table>	Type of supplies to be purchased with Country funds in each year	2018	2019	Number of vaccine doses	4,646,500	5,085,700	Number of AD syringes	4,861,500		Number of re-constitution syringes			Number of safety boxes	53,500		Value of vaccine doses (US\$)	5,018,145		Total co-financing payments (US\$) (including freight)	5,607,500	US\$5,985,500		
Type of supplies to be purchased with Country funds in each year	2018	2019																					
Number of vaccine doses	4,646,500	5,085,700																					
Number of AD syringes	4,861,500																						
Number of re-constitution syringes																							
Number of safety boxes	53,500																						
Value of vaccine doses (US\$)	5,018,145																						
Total co-financing payments (US\$) (including freight)	5,607,500	US\$5,985,500																					
<p>15. Operational support for campaigns: Not applicable</p>																							
<p>16. Additional reporting requirements:</p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>15 May 2018</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>			Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat															
Reports and other information	Due dates																						
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018																						
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat																						
<p>17. Financial clarifications: Not applicable</p>																							
<p>18. Other conditions: Not applicable</p>																							

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
13 December 2017